netrashetty
Netra Shetty
Becton, Dickinson and Company (BD) (NYSE: BDX), is an American medical technology company that manufactures and sells medical devices, instrument systems and reagents. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD does business in nearly 50 countries and has 28,803 employees worldwide.[2] In fiscal year ending Sep. 30 2009, 60% of BD sales were generated from non-U.S. markets.
The company's customers include healthcare institutions, clinical laboratories, industry and the general public. BD was one of the first companies to sell U.S.-made glass syringes. It was also a pioneer in the production of hypodermic needles. Today, BD is divided into three segments: BD Medical, BD Diagnostics and BD Biosciences.[3] BD was ranked 347 and 312, respectively, in the 2009 and 2010 Fortune 500 list.[4]
Benefits of Prefills
Prefills offer convenient, cost-effective parenteral delivery systems that help to reduce medication and dosing errors.
BD Innovative Self-Injection Systems
Revolutionary needle and packaging designs enhance injection comfort and safety.
BD Soluvia™ Intradermal Microinjection System
BD Soluvia™ is a prefillable microinjection system that is integrated with a tiny BD microneedle that allows the vaccine to be accurately delivered intradermally, within the dermal layer of the skin.
Press Release: BD Soluvia™ Microinjection System Used For First Approved Intradermal Influenza Vaccine in the European Union »
BD Expands Diagnostic Testing Offerings in Women’s Health »
BD Receives Health Canada Approval for the BD FocalPoint™ GS Imaging System to Enhance the Detection of Cervical Cancer »
Millions of patients and their doctors rely on the BD SurePath™ liquid-based Pap test every month to ensure their cervical health. »
BD Receives FDA Approval for the BD FocalPoint™ GS Imaging System to Enhance the Detection of Cervical Cancer »
Cervical Cytology products »
Molecular Oncology products »
Non-Gynecological applications »
Cervical cancer screening information for patients »
BD Diagnostics- Infectious Disease products have been developed to help improve patient outcomes by delivering cost-effective, rapid molecular and chromogenic testing solutions intended to aid in the prevention and control of healthcare-associated infections (HAIs). Our products provide laboratories with the capability to deliver critical, relevant information in a timeframe that enables significantly earlier clinical decisions.
Our current portfolio includes assays for Group B Streptococcus (GBS), methicillin-resistant Staphylococcus aureus (MRSA), C. difficile toxin B gene (tcdB), and a combination assay for methicillin-resistant Staphylococcus aureus and Staphylococcus aureus (MRSA and SA).
As an APIC Strategic Partner since 2006, BD is proud to support Infection Preventionists worldwide »
News & Events
BD Launches BD MAX™ System in U.S. to Empower Laboratories and Clinicians to Respond to Emerging Diseases »
BD and Diagenode Collaborate to Expand Infectious Disease Menu on the BD MAX™ System »
BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians »
BD Diagnostics and Lonza Collaborate to Commercialize the Lonza microCompass™ Molecular Assays on the BD MAX™ System »
BD Receives CLIA "Moderate Complexity" Status for the BD MAX™ GBS Assay »
BD Announces First FDA-Cleared Assay on the BD MAX™ System to Detect Group B Streptococcus »
BD Completes Acquisition of HandyLab, Inc. »
BD Adds Surveillance Capability to Infectious Disease Portfolio »
BD Announces FDA 510(k) Clearance of Novel Molecular Assay to Diagnose Clostridium difficile Infections »
BD Receives CE Mark Approval for Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures »
Learn More About...
Healthcare-Associated Infections At A Glance (PDF) »
BD LabO™ Spring 2010 issue features the BD GeneOhm™ Cdiff Assay (PDF) »
BD GeneOhm™ Cdiff Assay Backgrounder (PDF) »
BD Geneohm™ MRSA Assay At A Glance (PDF) »
Benefits of Rapid Testing (PDF) »
Key Research Papers Relevant to the BD GeneOhm™ MRSA Assay (PDF) »
BD LabO™ Winter 2007 issue features HAIs (PDF) »
BD
1 Becton Drive
Franklin Lakes, NJ USA 07417
201.847.6800
Unless otherwise noted, BD, BD Logo and all other trademarks are property of Becton, Dickinson and Com
The company's customers include healthcare institutions, clinical laboratories, industry and the general public. BD was one of the first companies to sell U.S.-made glass syringes. It was also a pioneer in the production of hypodermic needles. Today, BD is divided into three segments: BD Medical, BD Diagnostics and BD Biosciences.[3] BD was ranked 347 and 312, respectively, in the 2009 and 2010 Fortune 500 list.[4]
Benefits of Prefills
Prefills offer convenient, cost-effective parenteral delivery systems that help to reduce medication and dosing errors.
BD Innovative Self-Injection Systems
Revolutionary needle and packaging designs enhance injection comfort and safety.
BD Soluvia™ Intradermal Microinjection System
BD Soluvia™ is a prefillable microinjection system that is integrated with a tiny BD microneedle that allows the vaccine to be accurately delivered intradermally, within the dermal layer of the skin.
Press Release: BD Soluvia™ Microinjection System Used For First Approved Intradermal Influenza Vaccine in the European Union »
BD Expands Diagnostic Testing Offerings in Women’s Health »
BD Receives Health Canada Approval for the BD FocalPoint™ GS Imaging System to Enhance the Detection of Cervical Cancer »
Millions of patients and their doctors rely on the BD SurePath™ liquid-based Pap test every month to ensure their cervical health. »
BD Receives FDA Approval for the BD FocalPoint™ GS Imaging System to Enhance the Detection of Cervical Cancer »
Cervical Cytology products »
Molecular Oncology products »
Non-Gynecological applications »
Cervical cancer screening information for patients »
BD Diagnostics- Infectious Disease products have been developed to help improve patient outcomes by delivering cost-effective, rapid molecular and chromogenic testing solutions intended to aid in the prevention and control of healthcare-associated infections (HAIs). Our products provide laboratories with the capability to deliver critical, relevant information in a timeframe that enables significantly earlier clinical decisions.
Our current portfolio includes assays for Group B Streptococcus (GBS), methicillin-resistant Staphylococcus aureus (MRSA), C. difficile toxin B gene (tcdB), and a combination assay for methicillin-resistant Staphylococcus aureus and Staphylococcus aureus (MRSA and SA).
As an APIC Strategic Partner since 2006, BD is proud to support Infection Preventionists worldwide »
News & Events
BD Launches BD MAX™ System in U.S. to Empower Laboratories and Clinicians to Respond to Emerging Diseases »
BD and Diagenode Collaborate to Expand Infectious Disease Menu on the BD MAX™ System »
BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians »
BD Diagnostics and Lonza Collaborate to Commercialize the Lonza microCompass™ Molecular Assays on the BD MAX™ System »
BD Receives CLIA "Moderate Complexity" Status for the BD MAX™ GBS Assay »
BD Announces First FDA-Cleared Assay on the BD MAX™ System to Detect Group B Streptococcus »
BD Completes Acquisition of HandyLab, Inc. »
BD Adds Surveillance Capability to Infectious Disease Portfolio »
BD Announces FDA 510(k) Clearance of Novel Molecular Assay to Diagnose Clostridium difficile Infections »
BD Receives CE Mark Approval for Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures »
Learn More About...
Healthcare-Associated Infections At A Glance (PDF) »
BD LabO™ Spring 2010 issue features the BD GeneOhm™ Cdiff Assay (PDF) »
BD GeneOhm™ Cdiff Assay Backgrounder (PDF) »
BD Geneohm™ MRSA Assay At A Glance (PDF) »
Benefits of Rapid Testing (PDF) »
Key Research Papers Relevant to the BD GeneOhm™ MRSA Assay (PDF) »
BD LabO™ Winter 2007 issue features HAIs (PDF) »
BD
1 Becton Drive
Franklin Lakes, NJ USA 07417
201.847.6800
Unless otherwise noted, BD, BD Logo and all other trademarks are property of Becton, Dickinson and Com